511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 Genome

Julie Strizki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joan R. Butterton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jiejun Du(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alex G. Therien(Merck Canada Inc. (Canada)), Diane Levitan, Ying Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jay A. Grobler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shunbing Zhao(Merck & Co., Inc., Rahway, NJ, USA (United States))
Open Forum Infectious Diseases
November 1, 2021
10.1093/ofid/ofab466.710
Cited by 1

Related Papers

Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
|Science|2004|1.8k
Antibiotic Susceptibility Profiles of <i>Escherichia coli</i> Strains Lacking Multidrug Efflux Pump Genes
|Antimicrobial Agents and Chemotherapy|2001|502
Selective small-molecule inhibition of an RNA structural element
|Nature|2015|419
Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation
|Biochemical Journal|2006|272
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
|Clinical Infectious Diseases|2020|232